Hsu Yu-Lung, Chen Pei-Chi, Tsai Yi-Fen, Wei Chi-Hung, Wu Lawrence Shi-Hsin, Hsieh Kai-Sheng, Hsieh Miao-Hsi, Lai Huan-Cheng, Lin Chien-Heng, Lin Hsiao-Chuan, Chen Chieh-Ho, Chen An-Chyi, Lin Hung-Chih, Chou I-Ching, Soong Wen-Jue, Hwang Kao-Pin, Lu Henry Horng-Shing, Pawankar Ruby, Tsai Hui-Ju, Wang Jiu-Yao
Division of Pediatric Infectious Diseases, China Medical University Children's Hospital, China Medical University, Taichung 40447, Taiwan.
Graduate Institute of Biomedical Sciences, China Medical University, Taichung 40447, Taiwan.
Vaccines (Basel). 2024 Aug 12;12(8):910. doi: 10.3390/vaccines12080910.
Post-acute sequelae of SARS-CoV-2 infection (PASC) affects patients after recovering from acute coronavirus disease 2019 (COVID-19). This study investigates the impact of SARS-CoV-2 vaccination on PASC symptoms in children in Taiwan during the Omicron pandemic.
We enrolled children under 18 years with PASC symptoms persisting for more than 4 weeks. Data collected included demographics, clinical information, vaccination status, and symptom persistence. We used logistic regression models to compare symptoms in the acute and post-COVID-19 phases and to assess the association between vaccination and these symptoms.
Among 500 PASC children, 292 (58.4%) were vaccinated, 282 (52.8%) were male, and the mean (SD) age was 7.6 (4.6) years. Vaccinated individuals exhibited higher odds of experiencing symptoms in the previous acute phase, such as cough (adjusted odds ratio [AOR] = 1.57; 95% confidence interval [CI]: 1.02-2.42), rhinorrhea/nasal congestion (AOR = 1.74; 95% CI: 1.13-2.67), sneezing (AOR = 1.68; 95% CI: 1.02-2.76), sputum production (AOR = 1.91; 95% CI: 1.15-3.19), headache/dizziness (AOR = 1.73; 95% CI: 1.04-2.87), and muscle soreness (AOR = 2.33; 95% CI: 1.13-4.80). In contrast, there were lower odds of experiencing abdominal pain (AOR = 0.49; 95% CI: 0.25-0.94) and diarrhea (AOR = 0.37; 95% CI: 0.17-0.78) in children who had received vaccination during the post-COVID-19 phase.
This study revealed clinical features and vaccination effects in PASC children in Taiwan. Vaccination may reduce some gastrointestinal symptoms in the post-COVID-19 phase.
2019冠状病毒病（COVID-19）急性后遗症（PASC）影响急性感染严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）康复后的患者。本研究调查了在奥密克戎大流行期间，SARS-CoV-2疫苗接种对台湾儿童PASC症状的影响。
我们纳入了18岁以下PASC症状持续超过4周的儿童。收集的数据包括人口统计学、临床信息、疫苗接种状况和症状持续情况。我们使用逻辑回归模型比较急性和COVID-19后阶段的症状，并评估疫苗接种与这些症状之间的关联。
在500名PASC儿童中，292名（58.4%）接种了疫苗，282名（52.8%）为男性，平均（标准差）年龄为7.6（4.6）岁。接种疫苗的个体在前一急性期出现症状的几率更高，如咳嗽（调整后的优势比[AOR]=1.57；95%置信区间[CI]：1.02-2.42）、流涕/鼻塞（AOR=1.74；95%CI：1.13-2.67）、打喷嚏（AOR=1.68；95%CI：1.02-2.76）、咳痰（AOR=1.91；95%CI：1.15-3.19）、头痛/头晕（AOR=1.73；95%CI：1.04-2.87）和肌肉酸痛（AOR=2.33；95%CI：1.13-4.80）。相比之下，在COVID-19后阶段接种疫苗的儿童出现腹痛（AOR=0.49；95%CI：0.25-0.94）和腹泻（AOR=0.37；95%CI：0.17-0.78）的几率较低。
本研究揭示了台湾PASC儿童的临床特征和疫苗接种效果。疫苗接种可能会减少COVID-19后阶段的一些胃肠道症状。
